Accelerated healing of cutaneous leishmaniasis in non-healing BALB/c mice using water soluble amphotericin B-polymethacrylic acid

Biomaterials

Volumn 32, Issue 31, 2011, Pages 8029-8039

  Corware, Karina ^a   Harris, Debra ^a   Teo, Ian ^a   Rogers, Matthew ^b   Naresh, Kikkeri ^a   Müller, Ingrid ^b   Shaunak, Sunil ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

Author keywords

Antimicrobial; Controlled drug release; Drug delivery; Immunomodulation; Infection; Polymethacrylic acid

Indexed keywords

ANTIMICROBIAL; CONTROLLED DRUG RELEASE; IMMUNOMODULATION; INFECTION; POLYMETHACRYLIC ACID;

CELL CULTURE; DRUG DELIVERY; DRUG PRODUCTS; GLYCOPROTEINS; MACROPHAGES; MAMMALS; TISSUE; TOXIC MATERIALS;

REPAIR;

AMPHOTERICIN B; AMPHOTERICIN B POLYMETHACRYLIC ACID; GAMMA INTERFERON; INTERLEUKIN 10; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

AMASTIGOTE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FIBROBLAST; FOLLOW UP; HEALING; HISTOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEISHMANIA; MACROPHAGE; MOUSE; NONHUMAN; PARASITE CLEARANCE; PRIORITY JOURNAL; PROMASTIGOTE; SKIN LEISHMANIASIS; SOLUBILITY;

AMPHOTERICIN B; ANIMALS; CELL LINE; CHEMOKINES; DISEASE MODELS, ANIMAL; ERYTHROCYTES; HUMANS; HYPERSENSITIVITY, DELAYED; IMMUNOMODULATION; LEISHMANIA MAJOR; LEISHMANIASIS, CUTANEOUS; MACROPHAGES; MICE; MICE, INBRED BALB C; PARASITE LOAD; POLYMETHACRYLIC ACIDS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SOLUBILITY; SPECTROPHOTOMETRY, ULTRAVIOLET; TOXICITY TESTS; WATER; WOUND HEALING;

LEISHMANIA MAJOR; MUS;

EID: 80051816986     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.07.021     Document Type: Article

References (67)

1. Mahajan V.K., Sharma N.L. Therapeutic options for cutaneous leishmaniasis. J Dermatol Treat 2007, 18:97-104.
2. Reithinger R., Dujardin J.-C., Louzir H., Pirmez C., Alexander B., Brooker S., et al. Cutaneous leishmaniasis. Lancet Inf Dis 2007, 7:581-596.
3. Frankenburg S., Glick D., Klaus S., Barenholz Y. Efficacious topical treatment for murine cutaneous leishmaniasis with ethanolic formulations of AmB. Antimicrob Agents Chemother 1998, 42:3092-3096.
4. Yardley V., Croft S.L. A comparison of the activities of three AmB lipid formulations against experimental visceral and cutaneous leishmaniasis. Int J Antimicrob Agents 2000, 13:243-248.
5. Nelson K.G., Bishop J.V., Ryan R.O., Titus R. Nanodisk associated AmB clears L. major cutaneous infection in susceptible BALB/c mice. Antimicrob Agents Chemother 2006, 50:1238-1244.
6. Wortmann G., Zapor M., Ressner R., Fraser S., Hartzell J., Pierson J., et al. Lipsosomal AmB for treatment of cutaneous leishmania. Am J Trop Med Hyg 2010, 83:1028-1033.
7. Solomon M., Pavlotsky F., Leshem E., Ephros M., Trau H., Schwartz E. Liposomal AmB treatment of cutaneous leishmaniasis due to L. tropica. J Eur Acad Dermatol Venereol 2010 Dec 5, 10.1111/j.1468-3083.2010.03908.x.
8. Bolard J., Legrand P., Heitz F., Cybulska B. One sided action of AmB on cholesterol containing membranes is determined by its association in media. Biochemistry 1991, 30:5707-5715.
9. Legrand P., Romero E.A., Cohen E., Bolard J. Effects of aggregation and solvent on the toxicity of AmB to human erythrocytes. Antimicrob Agents Chemother 1992, 36:2518-2522.
10. Brajtburg J., Bolard J. Carrier effects on biological activity of AmB. Clin Microbiol Rev 1996, 9:512-531.
11. Kawabata M., Onda M., Mita T. Effect of aggregation of AmB on lysophosphatidylcholine micelles as related to its complex formation with cholesterol or ergosterol. J Biochem 2001, 129:725-732.
12. Olson J.A., Adler-Moore J.P., Jensen G.M., Schwartz J., Dignani M.C., Proffitt R.T. Comparison of the physicochemical, antifungal and toxic properties of two liposomal AmB products. Antimicrob Agents Chemother 2008, 52:259-268.
13. Sundar S., Mehta H., Suresh A.V., Singh S.P., Rai M., Murray H.W. AmB treatment for Indian visceral leishmaniasis: conventional versus lipid formulations. Clin Infect Dis 2004, 38:377-383.
14. Sundar S., Chakravarty J., Agarwal D., Rai M., Murray H.W. Single-dose liposomal AmB for visceral leishmaniasis in India. N Engl J Med 2010, 362:504-512.
15. Murray H.W., Brooks E.B., DeVecchio J.L., Heinzel F.P. Immuno-enhancement combined with AmB as treatment for experimental visceral leishmaniasis. Antimicrob Agents Chemother 2003, 47:2513-2517.
16. Sacks D., Noben-Trauth N. The immunology of susceptibility and resistance to L. major in mice. Nat Rev Immunol 2002, 2:845-858.
17. Stanley A.C., Engwerda C.R. Balancing immunity and pathology in visceral leishmaniasis. Immunol Cell Biol 2007, 85:138-147.
18. Noben-Trauth N., Kropf P., Müller I. Susceptibility to L. major infection in IL-4 deficient mice. Science 1996, 271:987-990.
19. Anderson C.F., Oukka M., Kuchroo V.J. Sacks, D. CD4+CD25-Foxp3-Th1 cells are the source of IL-10 mediated immune suppression in chronic cutaneous leishmaniasis. J Exp Med 2007, 204:285-297.
20. Belkaid Y., Hoffmann K.F., Mendez S., Kamhawi S., Udey M.C., Wynn T.A., et al. The role of IL-10 in the persistence of L. major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure. J Exp Med 2001, 194:1497-1506.
21. Murray H.W., Lau C.M., Mauze S., Freeman S., Moreira A.L., Kaplan G., et al. IL-10 in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy. Infect Immun 2002, 70:6284-6293.
22. Nagase H., Jones K.M., Anderson C.F., Noben-Trauth N. Despite increased CD4+Foxp3+ cells within the infection site, BALB/c IL-4 receptor-deficient mice reveal CD4+Foxp3- T-cells as a source of IL-10 in L. major susceptibility. J Immunol 2007, 179:2435-2444.
23. Zelikin A.N., Price A.D., Stadler B. Polymethacrylic acid polymer hydrogel capsules: drug carriers, sub-compartmentalized microreactors, artificial organelles. Small 2010, 6:2201-2207.
24. Mandel M., Leyte J.C., Stadhouder M.G. The conformational transition of polymethacrylic acid in solution. J Phys Chem 1967, 71:603-612.
25. Ikawa T., Abe K., Honda K., Tsuchida E. Interpolymer complex between polyethylene oxide and polycarboxylic acid. J Polym Sci 1975, 13:1505-1514.
26. Khutoryanskiy V.V. Hydrogen-bonded interpolymer complexes as materials for pharmaceutical applications. Int J Pharmaceutics 2007, 334:15-26.
27. Longo G.S., de la Cruz M.O., Szleifer I. Molecular theory of weak polyelectrolyte gels: the role of pH and salt concentration. Macromolecules 2011, 44:147-158.
28. Yessine M.-A., Leroux J.-C. Membrane-destabilizing polyanions: interaction with lipid bilayers and endosomal escape of biomacromolecules. Adv Drug Del Rev 2004, 56:999-1021.
29. Astier A., Doat B., Ferrer M.-J., Benoit G., Fleury J., Rolland A., et al. Enhancement of adriamycin antitumor activity by its binding with an intracellular sustained-release form, polymethacrylate nanospheres, in U-937 cells. Cancer Res 1988, 48:1835-1841.
30. Murthy N., Robichard J.R., Tirrell D.A., Stayton P.S., Hoffman A.S. The design and synthesis of polymers for eukaryotic membrane disruption. J Control Release 1999, 61:137-143.
31. Boudier A., Aubert-Pouëssel A., Louis-Plence P., Gérardin C., Jorgensen C., Devoisselle J.M. The control of dendritic cell maturation by pH-sensitive polyion complex micelles. Biomaterials 2009, 20:233-241.
32. Shaunak S., Thornton M., John S., Teo I., Peers E., Mason P., et al. Reduction of the viral load of HIV-1 after the intraperitoneal administration of dextrin 2-sulphate in patients with AIDS. AIDS 1998, 12:399-409.
33. Thornton M., Barkley L., Shaunak S. The anti-Kaposi's sarcoma and anti-angiogenic activity of sulphated dextrins. Antimicrob Agents Chemother 1999, 43:2528-2533.
34. Obeidat W.M., Abuznait A.H., Sallam A.S. Sustained release tablets containing soluble polymethacrylates: comparison with tableted polymethacrylate IPEC polymers. AAPS PharmSciTech 2010, 11:54-63.
35. Corware K.D., Rogers M., Teo I., Muller I., Shaunak S. An amphotericin B-based drug for treating Leishmania major infection. Trans Royal Soc Trop Med Hyg 2010, 104:749-750.
36. Espada R., Valdespina S., Alfonso C., Rivas G., Paloma Ballesteros M., Torrado J.J. Effect of aggregation state on the toxicity of different AmB preparations. Int J Pharm 2008, 361:64-69.
37. Shaunak S., Thomas S., Gianasi E., Godwin A., Jones E., Teo I., et al. Polyvalent dendrimer glucosamine conjugates prevent scar tissue formation. Nat Biotechnol 2004, 22:977-985.
38. Locksley R.M., Heinzel F.P., Sadick M.D., Holaday B.J., Gardner K.D. Murine cutaneous leishmaniasis susceptibility correlates with differential expansion of helper T cell subsets. Ann Inst Pasteur/Immunol 1987, 138:744-749.
39. Katzman S.D., Fowell D.J. Pathogen imposed skewing of mouse chemokine and cytokine expression at the infected tissue site. J Clin Invest 2008, 118:801-811.
40. Bell W.J., Meinardus-Hager G., Neugebauer D.C., Sorg C. Differences in the onset of the inflammatory response to cutaneous leishmaniasis in resistant and susceptible mice. J Leucoc Biol 1992, 52:135-142.
41. Titus R.G., Marchand M., Boon T., Louis J.A. A limiting dilution assay for quantifying L. major in tissues of infected mice. Parasite Immunol 1985, 7:545-555.
42. Tacchini-Cottier F., Zweifel C., Belkaid Y., Mukankundiya C., Vasei M., Launois P., et al. An immuno-modulatory function for neutrophils during the induction of a CD4+ Th2 response in BALB/c mice infected with L. major. J Immunol 2000, 165:2628-2636.
43. Odo M.E.Y., Cuce L.C., Odo L.M., Natrielli A. Action of sodium deoxycholate on subcutaneous human tissue: local and systemic effects. Dermatol Surg 2007, 33:178-189.
44. Schuller-Petrovic S., Wolkart G., Hofler G., Neuhold N., Freisinger F., Brunner F. Tissue toxic effects of phosphatidylcholine/deoxycholate after subcutaneous injection for fat dissolution in rats and a human volunteer. Dermatol Surg 2008, 34:529-543.
45. Oussoren C., Eling W.M.C., Crommelin D.J.A., Storm G., Zuidema J. The influence of the route of administration and liposome composition on the potential of liposomes to protect tissue against local toxicity of two antitumor drugs. Biochim Biophys Acta 1998, 1369:159-172.
46. Kadir F., Eling V.M., Abrahams D., Zuidema J., Crommelin D.J. Tissue reaction after intramuscular injection of liposomes in mice. Int J Clin Pharmacol Ther Toxicol 1992, 30:374-382.
47. Corware K. Modifying AmB for the treatment of cutaneous leishmaniasis. PhD thesis. Imperial College London; 2010.
48. Harris D. A homopolymer complex of AmB for the pharmacological treatment and immunotherapy of leishmaniasis. PhD thesis. University of London; 2006.
49. Iezzi G., Frölich A., Ernst B., Ampenberger F., Saeland S., Glaichenhaus N., et al. Lymph node resident rather than skin derived dendritic cells initiate specific T cell responses after L. major infection. J Immunol 2006, 177:1250-1256.
50. Cangussú S.D., de Souza C.C., Campos C.F., Vieira L.Q., Afonson L.C.C., Arantes R.M. Histopathology of L. major infection: revisiting L. major histopathology in the ear dermis infection model. Mem Inst Oswaldo Cruz 2009, 104:918-922.
51. Murray H.W., Delph-Etienne S. Roles of endogenous IFN-γ and macrophage microbicidal mechanisms in host response to chemotherapy in experimental visceral leishmaniasis. Infect Immun 2000, 68:288-293.
52. Murphy M.L., Wille U., Villegas E.N., Hunter C.A., Farrell J.P. IL-10 mediates susceptibility to L. donovani infection. Eur J Immunol 2001, 31:2848-2856.
53. Merigan T.C., Finkelstein M.S. Interferon stimulating and in vivo antiviral effects of various synthetic anionic polymers. Virology 1968, 35:363-374.
54. Otterlei M., Ostgaard K., Skjåk-Braek G., Smidsrød O., Soon-Shiong P., Espevik T. Induction of cytokine production from human monocytes stimulated with alginate. J Immunother 1991, 10:286-291.
55. Flo T.H., Ryan L., Latz E., Takeuchi O., Monks B.G., Lien E., et al. Involvement of TLR2 and TLR4 in cell activation by mannuronic acid polymers. J Biol Chem 2002, 277:35489-35495.
56. Cohen Stuart M.A., Huck W.T.S., Genzer J., Muller M., Ober C., Stamm M., et al. Emerging applications of stimuli-responsive polymer materials. Nat Mater 2010, 9:101-113.
57. Moore K., Matlashewski G. Intracellular infection by L. donovani inhibits macrophage apoptosis. J Immunol 1994, 152:2930-2937.
58. Carrera L., Gazzinelli R.T., Badolato R., Hieny S., Muller W., Kuhn R., et al. Leishmania promastigotes selectively inhibit IL-12 induction in bone marrow derived macrophages from susceptible and resistant mice. J Exp Med 2006, 183:515-526.
59. Belkaid Y., Butcher B., Sacks D.L. Analysis of cytokine production by inflammatory mouse macrophages at the single-cell level: selective impairment of IL-12 induction in Leishmania infected cells. Eur J Immunol 1998, 28:1389-1400.
60. Buates S., Matlashewski G. General suppression of macrophage gene expression during L. donovani infection. J Immunol 2001, 166:3416-3422.
61. Lee N., Bertholet S., Debrabant A., Muller J., Duncan R., Nakhasi H.L., et al. Programmed cell death in the unicellular protozoan parasite Leishmania. Cell Death Differ 2002, 9:53-64.
62. Hondowicz B., Scott P. Influence of parasite load on the ability of Th1 T-cells to control L. major infection. Infect Immun 2002, 70:498-503.
63. Kropf P., Freudenberg M.A., Modolell M., Price H.P., Herath S., Antoniazi S., et al. TLR4 contributes to efficient control of infection with the protozoan parasite L. major. Infect Immun 2004, 72:1920-1928.
64. Lecoeur H., Buffet P., Morizot G., Goyard S., Guigon G., Milon G., et al. Optimization of topical therapy for L. major localized cutaneous leishmaniasis using a reliable C57BL/6 model. PLoS Negl Trop Dis 2007, 1(2):e34. 10.1371/journal.pntd.0000034.
65. Lee J.W., Park J.-H., Prausnitz M.R. Dissolving microneedles for transdermal drug delivery. Biomaterials 2008, 29:2113-2124.
66. Sullivan S.P., Murthy N., Prausnitz M.R. Minimally invasive protein delivery with rapidly dissolving polymer microneedles. Adv Mater 2008, 20:933-938.
67. Lee J.W., Choi S.O., Felner E.I., Prausnitz M.R. Dissolving microneedle patch for transdermal delivery of human growth hormone. Small 2011, 7:531-539.